Mindrank AI secured a $52 million Series B to advance MDR-001, an AI-discovered oral small-molecule GLP-1 receptor agonist already in phase 3 trials for obesity in China. The financing is positioned to scale the company’s drug discovery engine and support clinical execution as oral GLP-1 competition intensifies globally.